Alpha1-antitrypsin (AAT) deficiency is an under-diagnosed condition in patients with chronic obstructive pulmonary disease (COPD). The aim of our study was to evaluate predictive value of quantitative methods of alpha-1 antitrypsin for Z mutation detection in patients with chronic obstructive pul monary disease. Ninety-one AAT deficiency genotypes (40 MZ, 39 MS, 1 SS, 3 SZ and 8 ZZ) were analysed. Calculated sensitivity of quantitative alpha-1 antitrypsin measurement by nephe lometry for heterozygous PI*Z allele was 45% and for homozygous ZZ genotype -88%. Specificity of quantitative alpha-1 antitrypsin analysis for heterozygous deficiency was 98% and for homozygous deficiency -100%. Thus sensitivity of quantitative al pha-1 antitrypsin analysis is higher than specificity for bothheterozygous and homozygous deficiency.
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent and costly disease characterized by progressive airflow limitation and related to an abnormal inflammatory response of the lung to long-term tobacco smoking or gases inhalation (Global Initiative..., 2006). A mixture of bronchiolitis and lung emphysema causes the airflow limitation. The best documented genetic risk factor is severe hereditary deficiency of alpha-1 antitrypsin (AAT), a genetic disor der most commonly seen in individuals of Northern, Western and Central Europe origin (Blanco et al., 2006; De . AAT is a 52 kDa alpha-1-glycoprotein produced mainly by hepatocytes and secreted into the blood, where it acts as a circulating serine protease inhibitor. AAT permeates most body tissues where it acts as a broad-spectrum anti -infl ammatory and connective tissue repair er molecule, which modulates most infl ammatory reactions occurring in the human body ( AAT deficiency can be suspected by quantitative serum analysis, however, only detection of gene mutation confirms the exact diagno sis. The aim of our study was to evaluate sensitivi ty of quantitative method which is usually used for screening of AAT deficiency.
MATERIALS AND METHODS

Sample analysis
Serum alpha-1 antitrypsin concentration from patients (n = 1 167) with chronic obstructive pulmonary disease, defined according to the GOLD criteria, was analysed by nephelometry, alpha-1 antitrypsin genotype was determined by means of isoelectric-focusing. 
Calculations and statistical analyses
RESULTS
As it is shown in Table, the cohort consisted of 1 167 patients with COPD. Genotypes distribution (number and percentage) was as follows: 1 076 (92.2%) MM, 40 (3.4%) MZ, 39 (3.3%) MS, 1 (0.1%) SS, 3 (0.3%) SZ and 8 (0.7%) ZZ. The ZZ patients were younger (54 ± 11 years, p < 0.05) compa red to the MM, MS, MZ patients. The majo rity of the studied COPD patients were men (72%). Such high number of men with COPD in Lithuania could be explained by smoking habits. According to the Finbalt Health Mo nitor Programme, the number of male smokers in the general Lithuanian po pulation is 6.9 times higher than the number of female smokers (Grabauskas et al., 2002) . All 1 167 samples were processed both for the quantification of AAT and determination of PI*Z deficiency allele. The mean AAT serum con centration was 1.58 ± 0.43 g/l. As it was ex pected, we found significant differences in serum AAT con centrations comparing groups (p < 0.05). The ZZ group showed a significantly lower se rum AAT concentration (0.40 ± 0.34 g/l) as com pared to other genotype groups (Fig. 1) .
Concentrations above the cut-off point estab lished as normal were detected in 1 134 samples (97.2%) and 33 samples (2.8%) pre sented low concentration (Fig. 2) . Among the individuals with normal concentrations the PI*Z allele was not detected in 1 111 (98.0%) and was detected in 23 (2%) patients (Fig. 2) .
Calculated sensitivity of quantitative AAT measurement by nephelometry for hete ro- zygous PI*Z allele was 45% and for ho mozygous ZZ genotype -88%. Specificity of quantitative alpha-1 antitrypsin analysis for heterozygous deficiency (PI*Z allele) was 98% and for homozygous deficiency -100%.
DISCUSSION
The diagnosis of AAT deficiency is relatively simple, however population studies have indicated that this disease is under-diagnosed and a delay in diagnosis is very common up till now (Global Initiative..., 2006; GarciaRio et al., 2010). The present study comparing the ZZ group against all remaining 5 genotypes groups shows: a lower AAT serum concentration (0.40 g/L, significant difference of p < 0.05), thus in Lithuania alpha-1 antitrypsin deficiency ZZ almost always is detected during scientific projects but not during common clinical practice. The quantifying of AAT concentration is very important for identifying in dividuals with congenital AAT deficiency in screening purposes. However, our study show ed that quantitative method's sensitivity for heterozygous PI*Z mutation is only 45% and for homozygous ZZ genotype -8%. The most striking finding was that even a severe homozygous ZZ deficiency was found in one subject with normal AAT concentration. We speculate that it could be because of bronchial da mage due to terminal stage of disease. This COPD patient had very low FEV 1 value (15% predicted) although general inflammatory markers were not elevated (CRP 3 mg/l). It shows that the presence of false negative results did not allow all samples with normal concentrations to be qualified as non-deficient.
In heterozygous state a quantitative test may not allow detection of some individuals possibly due to pathophysiological inflammatory processes. Even smoking in COPD patients may be associated with higher AAT and CRP production in the liver of COPD patients and me chanisms connected with systemic inflammation which continues even after cessation of smok ing. Even in healthy individuals, positive associations between active smoking and AAT levels have been reported before (Senn et al., 2008) . The quantity of AAT that diffuses passively from the blood to the lung increases during an inflammatory process which takes place in COPD (Grabauskas et al., 2002) . This may indicate an increased requirement of AAT to meet the needs of overcoming the release of various en zymes from neutrophilic cells in the lungs, but its protective function may be overrun by the high concentration of proteases (Stockley et al., 2009) . Increase of AAT level in smokers and ex-smokers reflects the dual role of AAT as a res piratory disease biomarker. The net impact of AAT on lung function seems to be a result of context-dependent (i. e. AAT genotype) and contrasting protective and inflammatory effects in respiratory tract. On the one hand, elevated serum AAT can reflect a beneficial shift in the protease-antiprotease balance, the centre piece of the pathophysiological pathway mediating the effect of severe congenital AAT deficiency on COPD. On the other hand, elevated serum AAT can also reflect low-grade inflammatory processes in the lung (Langereis et al., 2011; Serapinas et al., 2011) it is hypothesized COPD risk factor.
In European countries, AAT deficiency detection programs have been carried out by using different methodologies. Case control stu dies demonstrated an increase in the preva lence of PI*Z heterozygotes in patients with COPD compared with the control group when using genotyping methods (Senn et In their study the authors used a dried blood spot on filter paper since it is the method used in screening of other genetic diseases. They found similar sensitivity for detection of heterozy gous PI*Z mutation -60%. And for homozygous ZZ genotype (in total 4 cases) sensitivity was 100%. In another program undertaken in Italy the detection rate for ZZ was 6.4% (Luisetti et al., 1999) . The higher rate of ZZ cases in that study could be due to the design of the study because only COPD patients with clinical suspicion or familial AAT deficiency were selected and to all patients genotyping was performed. In another recent study performed in Germany in 2 272 samples, making pre-screening by determining the AAT serum levels by the submitting physi cians, the detection rate in the selected cases with low AAT serum concentrations sig ni ficant ly increased, and 335 patients with se vere AAT deficiency, including 16 individuals with rare genotypes, were identified from the studied subjects (Bals et al., 2007) . Our results are close to the data received from the study car ried out in Denmark: frequency of AAT de ficiency in COPD patients was ZZ 0.8% (Dahl et al., 2002) .
The results of the present study support the general concept of targeted screening for AAT deficiency with adequate laboratory methods in European countries with PI*Z high frequency and large population of COPD patients with highest diagnostic value -AAT genotyping. A case detection programme of alpha-1 antitrypsin deficiency in patients with chronic obstructive pulmonary disease using quantitative methods could be used only in screening programs and the exact diagnosis must be confirmed by determining AAT ge no type.
In conclusion, when designing a case detection programme both the protocol of sample processing and the inclusion criteria for the candidates should be taken into account since both factors have a decisive impact on the performance of the programme.
